Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Bioxyne Limited ( (AU:BXN) ) has provided an announcement.
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has entered the German cannabis market by securing a manufacture and supply agreement worth €3.2 million (A$5.6 million) with Farmakem d.o.o. and Adrex Pharmaceuticals GmbH. This agreement involves supplying a minimum of 1,600 kg of GMP-certified medical cannabis flower, with the first delivery scheduled for September 2025. The German medical cannabis market is rapidly growing, and Bioxyne’s entry is expected to bolster its growth in FY2026, leveraging its GMP certification for competitive advantages in Germany and other European markets.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical company that manufactures and distributes novel medicines and active pharmaceutical ingredients, including medicinal cannabis, MDMA, and Psilocybin.
Average Trading Volume: 3,380,342
Technical Sentiment Signal: Buy
Current Market Cap: A$58.45M
For an in-depth examination of BXN stock, go to TipRanks’ Overview page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue